NEW YORK CITY, NEW YORK (WBRE/WYOU) – Facing continued public outrage over the high cost of it’s potentially life-saving EpiPen, Mylan announced Monday it will produce a generic version of the medication.

The company says its U.S. based subsidiary will put out the generic version with a list-price of $300 for a twin pack of the pens, about half the cost of its name-brand product.

The pens are used in emergencies to treat severe allergic reactions to insect bites and foods like nuts and eggs by relaxing the muscles of the throat to help people breathe.

Mylan has been the target of public outrage for the past 10-days after it was revealed the price of its name-brand product, which comes with two injectors, has climbed more than 400% over the past seven years to $608 per pack.

Last week, Mylan said it would offer a $300 savings card to those with high deductibles or no insurance for its name-brand product, and would revise its patient assistance program to make the pens more affordable.

Among other users, all schools are required to have the pens in the event of an allergic reaction.